Skip to content
    back

    Supporting your cell and gene therapy manufacturing process

    Curing diseases instead of merely treating symptoms – that’s the transformative promise of cell and gene therapies (CGTs). From autologous therapies like CAR-T cells to allogeneic cell therapies, the market is growing at a rapid pace. While most process steps in manufacturing are still performed manually today, biopharmaceutical manufacturers need to prepare now for commercial production. Syntegon is here to support you with matching equipment and seamless support throughout your product and project lifecycle.

    Connect with our experts

    Facts and figures

    Sales forecast for cell and gene therapies from 2024 to 2030 showing 40% CAGR growth

    Cell and gene therapies – a rapidly growing market

    With hundreds of cell and gene therapies in clinical trials, the CGT market is one of the most dynamic in the current pharmaceutical landscape. According to GlobalData, analysts forecast it will grow with an average of 40% p.a. between 2024 and 2030.

    Of the more than 31,000 injectable products currently on the market (as of March 2025), biologics represent 12%. However, the picture shifts significantly when looking at the clinical pipeline: biologics now make up around 84% of the approximately 6,500 injectable therapies in development. Of these biologics, 34% fall under the category of cell and gene therapies. This group can be further divided into three segments: cell therapies (35%), gene therapies (16%), and gene-modified therapies (49%).

    Bar chart showing breakdown of marketed vs. clinical pipeline injectables by type, highlighting biologics and share of cell & gene therapies

    One of the main obstacles to the market adoption of cell and gene therapies is their high cost. Treatments such as CAR-T cell therapies often amount to several hundred thousand US dollars per patient, while altogether prices for CGTs can be as high as 4 million USD per treatment. These figures primarily reflect the substantial costs associated with development and manufacturing.

    A major cost driver is the reliance on manual production processes. To reduce expenses and improve accessibility, scaling up and automating manufacturing is essential. This is key to making CGTs more cost-effective and facilitating broader patient access. A challenge that we at Syntegon are happy to tackle together with you.

    Contact us

    Solving your cell and gene manufacturing challenges

    3D illustration of a cleanroom production facility for cell and gene therapies with isolated workstations and equipment
    From manual to automated processes

    Currently, most cell and gene therapies are still produced manually. Syntegon offers both manual solutions from our subsidiaries Klenzaids and Telstar, and automated solutions for small batch filling. We are ready to bridge the gap together with you.

    View our small batch portfolio
    Syntegon experts in a meeting room discussing GMP-compliant production processes
    Ensuring GMP compliance

    Implementing efficient ATMP manufacturing processes under GMP conditions is no easy task – especially if you are not accustomed to commercial production. Our experts have many years of experience. They know exactly what it takes to bring a product into production and will be happy to support you.

    Discover our GMP services
    Digital illustration of a connected world representing global growth and innovation
    Preparing for the future

    According to Globaldata, analysts forecast that the cell and gene therapy market will grow with an average of 40% p.a. between 2024 and 2030. Get in touch with our experts to see how we can support you with seamless consulting and equipment concepts to gain your market share.

    Connect with our experts

    Discover the right path for Cell&Gene manufacturing

    Discover how Syntegon can support you in your cell and gene projects with seamless support along your product and project lifecycle – from consulting to fully automated equipment solutions and sustainable services.

    • Market studies
    • GMP Consulting
    • Biosafety cabinets
    • Low temperature Freezers
    • Containment

    • Market studies
    • GMP Consulting
    • Biosafety cabinets
    • Low temperature Freezers
    • Containment
    • Microbatch
    • Pure Media
    • Sterilisation

    • GMP Consulting
    • Microbatch
    • Pure Media
    • Sterilisation

    • After Sales
    • GMP Consulting
    • Microbatch
    • Pure Media
    • Sterilisation
    Digital visualization of a DNA double helix with glowing connection nodes representing biotechnology and innovation

    Why choose Syntegon?

    Syntegon is your ideal strategic partner for your cell and gene therapy manufacturing process. You receive seamless support along your entire product and project lifecycle – from consulting to equipment and services. Rely on our long-standing experience, global presence, and innovative technologies. Together, we will enhance the time to market of your cell and gene therapies.

    Contact us
    Service Agreements
    Service Agreements

    Find out more about our Service Agreements here.

    Learn more
    Digital Solutions
    Digital Solutions

    Find out more about Digital Solutions here.

    Learn more
    Maintenance
    Maintenance

    Find out more about Maintenance here.

    Learn more
    Technical Support
    Technical Support

    Find out more about Technical Support here.

    Learn more
    Modernizations
    Modernizations

    Find out more about Modernizations here.

    Learn more
    Training
    Training

    Find out more about our Training here.

    Learn more
    Expert Services
    Expert Services

    Find out more about our Expert Services here.

    Learn more
    deposit-photos-03

    Interested in Cell and gene therapies?

    Contact us

    Read our latest pharma news

    FCE Pharma: Prazer em conhecê-lo
    13.05.2025
    FCE Pharma: Prazer em conhecê-lo

    Join us at FCE Pharma, Latin America's largest pharmaceutical event! Visit Syntegon at booth C-80 from June 10-12, 2025, to discover our latest innovations

    More
    Smart solutions for efficient vaccine manufacturing
    Smart solutions for efficient vaccine manufacturing

    Discover Syntegon, a leader in vaccine manufacturing equipment with over 30 years of experience and...

    More
    Pharmatag 2025: Let’s shape the pharmaceutical future together
    Pharmatag 2025: Let’s shape the pharmaceutical future together

    Join us at Pharmatag 2025 in Crailsheim, Germany, and experience how co-creation revolutionizes...

    More
    Syntegon enhances inspection portfolio with RTU handling equipment
    Syntegon enhances inspection portfolio with RTU handling equipment

    Stay informed about the booming RTU syringe market and Syntegon's AIM DIRect, featuring...

    More
    TPR tablet presses from Syntegon: a long history of successful innovation
    TPR tablet presses from Syntegon: a long history of successful innovation

    Discover the TPR tablet compression range from Syntegon, a trusted name in OSD drug manufacturing...

    More
    More Syntegon News